VERACYTE, INC. VCYT Income Statement

Veracyte, inc. (VCYT)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Sep'12
Total Revenue
121,961	120,368	116,388	108,881	101,496	92,008	85,854	79,907	75,562	71,953	70,614	71,698	67,967	65,085	60,870	54,602	51,835	49,503	47,660	45,163	41,932	38,190	32,829	28,585	24,976	21,884	18,270	0	0	0
Operating expenses:
Cost of testing revenue
-	36,077	35,108	34,255	33,724	33,078	32,143	31,051	29,765	28,195	26,941	26,139	25,480	25,462	25,121	24,372	23,210	21,497	20,188	18,738	17,565	16,606	15,212	14,176	13,441	12,607	11,120	0	0	0
Research and development
15,823	14,851	13,533	13,309	14,580	14,820	14,897	14,524	13,526	13,881	14,269	15,229	15,893	15,324	15,077	14,634	13,470	12,796	12,655	11,325	10,465	9,804	8,472	8,267	7,926	7,810	7,669	0	0	0
Selling and marketing
58,798	53,691	49,574	46,567	42,247	41,313	40,292	38,096	36,467	32,260	29,047	28,249	28,518	28,248	29,104	28,065	26,739	25,293	25,567	25,052	23,216	21,932	18,901	16,659	14,173	12,540	10,956	0	0	0
General and administrative
29,938	29,029	27,093	26,211	25,223	23,963	22,675	22,453	22,713	23,088	23,456	23,699	23,578	23,787	23,583	23,548	23,013	22,583	22,291	22,278	20,670	18,854	16,953	14,482	13,291	12,100	10,875	0	0	0
Intangible asset amortization
2,409	1,401	1,067	1,067	1,067	1,067	1,067	1,067	1,067	1,067	1,067	1,066	1,067	1,067	1,066	1,067	0	-	0	0	-	-	-	-	-	-	-	-	-	-
Total operating expenses
147,221	135,495	126,375	121,409	116,841	114,241	111,074	107,191	103,538	98,491	94,780	94,382	94,536	93,888	93,952	91,686	87,499	82,969	81,234	77,660	71,916	67,196	59,538	53,584	48,831	45,057	40,620	0	0	0
Loss from operations
-25,260	-15,127	-9,987	-12,528	-15,345	-22,233	-25,220	-27,284	-27,976	-26,538	-24,166	-22,684	-26,569	-28,803	-33,082	-37,084	-35,664	-33,466	-33,574	-32,497	-29,984	-29,006	-26,709	-24,999	-23,855	-23,173	-22,350	0	0	0
Interest expense
429	677	1,132	1,572	1,818	1,963	3,945	4,262	4,589	4,941	3,229	3,213	3,190	2,757	2,058	1,351	656	378	372	394	417	439	464	355	0	-	0	0	-	-
Other income, net
3,291	3,205	2,873	2,115	1,424	1,197	832	633	602	476	428	342	259	202	172	159	151	140	113	101	92	72	26	-73	-1,160	-2,174	-2,145	0	0	0
Net loss and comprehensive loss
-22,398	-12,599	-8,246	-11,985	-15,739	-22,999	-28,333	-30,913	-31,963	-31,003	-26,967	-25,555	-29,500	-31,358	-34,968	-38,276	-36,169	-33,704	-33,833	-32,790	-30,309	-29,373	-27,123	-25,524	-25,359	-25,580	-24,626	0	0	0
Comprehensive loss
-22,398	-12,599	-8,246	-11,985	-15,739	-22,999	-28,333	-30,913	-31,963	-31,003	-26,967	-25,555	-29,500	-31,358	-34,968	-38,276	-36,169	-33,704	-33,833	-32,790	-30,309	-29,373	-27,534	0	0	-	0	-	-	-
Net loss per common share, basic and diluted (in usd per share)
-0.24	-0.15	-0.02	-0.05	-0.05	-0.05	-0.12	-0.18	-0.27	-0.24	-0.21	-0.22	-0.24	-0.13	-0.20	-0.40	-0.36	-0.29	-0.32	-0.35	-0.34	-0.36	-0.37	-0.31	-0.32	17.01	-6.59	-7.53	-9.04	-7.49
Shares used to compute net loss per common share, basic and diluted (in shares)
49,792	49,209	48,588	45,586	41,168	40,875	38,620	34,314	34,271	34,058	33,946	33,873	33,823	31,727	27,916	27,859	27,817	27,747	27,640	26,048	22,539	22,523	21,648	21,237	21,148	14,053	955	861	763	659
Testing
Total Revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of testing revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product
Total Revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of testing revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Biopharmaceutical
Total Revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of testing revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-